Upon binding to their respective receptor complexes, all IL-20 subfamily members initiate activation of the Janus kinase (JAK) and STAT pathway, with a particular emphasis on STAT3, aberrantly hyperactivated in many types of cancer and generally associated with a poor clinical prognosis [34,35]. This evidence concerns the gene IL20 and cancer.